Table 2 List of colorectal cancer cases used in the immunohistochemistry assays.

From: Novel monoclonal antibody L2A5 specifically targeting sialyl-Tn and short glycans terminated by alpha-2–6 sialic acids

Patient/Sample

Histology/Stage

L2A5

B72.3

Extension (%)

Intensity

Extension (%)

Intensity

CRC1

Adenoma

40

Moderate

20

Weak

CRC2

Adenoma

10

Weak

10

Weak

CRC 3

T1

25

Moderate

20

Weak

CRC 4

T1

60

Weak

0

Negative

CRC 5

T2

90

Moderate

90

Moderate

CRC 6

T2

5

Weak

5

Weak

CRC 7

T2

55

Moderate

30

Moderate

CRC 8

T2

90

Moderate

40

Moderate

CRC 9

T3

20

Weak

10

Weak

CRC 10

T3

60

Moderate

50

Moderate

CRC 11

T3

80

Strong

80

Strong

CRC 12

T3

40

Weak

40

Weak

CRC 13

T3

75

Moderate

60

Weak

CRC 14

T4

50

Strong

40

Strong

  1. Comparison of immunohistochemical staining results of L2A5 and B72.3 mAbs represented as staining intensity and percentage of cells stained.
  2. Note: Tumour stages are defined according to TNM classification. Each colorectal cancer sample was numbered CRCX.